Plus Therapeutics (PSTV) Cash from Investing Activities (2010 - 2026)
Plus Therapeutics (PSTV) reported Cash from Investing Activities of -$8.5 million for Q1 2026, down 339.83% year-over-year from $3.6 million in Q1 2025, and down 692.29% quarter-over-quarter from -$1.1 million in Q4 2025.
Plus Therapeutics (PSTV) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 17 years of Cash from Investing Activities data on file, last reported at -$8.5 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$8.5 million, down 339.83% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12.9 million (down 6749.21% YoY), and the FY2025 annual result was -$854000.0, up 79.23% from the prior year.
- Cash from Investing Activities slipped to -$8.5 million in Q1 2026 per PSTV's latest filing, from -$1.1 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $3.6 million in Q1 2025 and troughed at -$8.5 million in Q1 2026.
- A 5-year average of -$848058.8 and a median of -$42000.0 in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities sank 34463.64% in 2024, then soared 14511.11% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at -$11000.0 in 2022, then plunged by 281.82% to -$42000.0 in 2023, then surged by 252.38% to $64000.0 in 2024, then sank by 1782.81% to -$1.1 million in 2025, then tumbled by 692.29% to -$8.5 million in 2026.
- Business Quant data shows PSTV's Cash from Investing Activities at -$8.5 million in Q1 2026, -$1.1 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 579,519.10 |
| 10 | Plus Therapeutics | 34.26 Mn | 19.15 Mn | - | -8.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.53 Mn |
| Mar 31, 2026 | -8.53 Mn |
| Dec 31, 2025 | -1.08 Mn |
| Dec 31, 2025 | -1.08 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | -4.63 Mn |
| Jun 30, 2025 | -4.63 Mn |
| Mar 31, 2025 | 3.56 Mn |
| Mar 31, 2025 | 3.56 Mn |
| Dec 31, 2024 | 64,000.00 |
| Dec 31, 2024 | 64,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Jun 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -3.80 Mn |
| Mar 31, 2024 | -364,000.00 |
| Mar 31, 2024 | -364,000.00 |
| Dec 31, 2023 | -42,000.00 |
| Dec 31, 2023 | -42,000.00 |